To the Editor.—
Colony-stimulating factors are being used as supportive treatment for a multitude of systemic disorders, such as the human immunodeficiency virus, myelodysplasia, aplastic anemia, neutropenias, and chemotherapeuticinduced bone marrow toxicity.1 All of these factors are produced by various cells within the skin, and their exact roles in cutaneous diseases are yet to be delineated. Administration of colony-stimulating factors is performed via intravenous or subcutaneous routes, and localized as well as generalized cutaneous reactions have been reported.1,2 We observed localized cutaneous reactions associated with granulocyte colony-stimulating factor injections that were clinically and histologically similar to those observed for granulocyte-monocyte colony-stimulating factor. A pronounced eosinophil infltrate was observed despite the fact that, unlike granulocyte-monocyte colony-stimulating factor, granulocyte colony-stimulating factor does not promote eosinophil differentiation or activation.1
Report of a Case.—
A 61-year-old Filipino woman presented with symptoms of chronic low back pain. Serum protein electrophoresis and bone
Samlaska CP, Noyes DK. Localized Cutaneous Reactions to Granulocyte Colony-Stimulating Factor. Arch Dermatol. 1993;129(5):645–646. doi:10.1001/archderm.1993.01680260117022
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.